Last reviewed · How we verify
A. Chilensis
A. Chilensis is a botanical extract with potential immunomodulatory and antioxidant properties.
At a glance
| Generic name | A. Chilensis |
|---|---|
| Sponsor | Vedic Lifesciences Pvt. Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
A. Chilensis (likely Aloe chilensis or a related species) is traditionally used in herbal medicine and may exert therapeutic effects through polysaccharide and phenolic compound-mediated immune stimulation and free radical scavenging. The exact molecular mechanisms in clinical development by Vedic Lifesciences remain proprietary and not fully characterized in peer-reviewed literature.
Approved indications
Common side effects
Key clinical trials
- Gummy Candies With Maqui Berry (NA)
- To Compare the Efficacy and Tolerability of A. Paniculata/A. Chilensis in Individuals With URTI (PHASE3)
- Evaluate the Improving Effects of Visucomplex Plus on Quality of Life in Patients With AMD
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- A. Chilensis CI brief — competitive landscape report
- A. Chilensis updates RSS · CI watch RSS
- Vedic Lifesciences Pvt. Ltd. portfolio CI